A carregar...

Phase I dendritic cell p53 peptide vaccine for head and neck cancer

BACKGROUND: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against p53 was tested in a phase I clinical trial. METHODS: Monocyte-derived DC from 16 patients were loaded with two modified HLA-c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schuler, Patrick J., Harasymczuk, Malgorzata, Visus, Carmen, DeLeo, Albert, Trivedi, Sumita, Lei, Yu, Argiris, Athanassios, Gooding, William, Butterfield, Lisa H., Whiteside, Theresa L., Ferris, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017234/
https://ncbi.nlm.nih.gov/pubmed/24583792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2617
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!